{
  "drug_name": "Encainide",
  "url": "https://wikem.org/wiki/Encainide",
  "scraped_at": "2026-01-10T07:52:37.367204",
  "sections": {
    "Administration": {
      "text": "Type: Class IC antiarrhythmic (sodium channel blocker)\nDosage Forms: Capsules (25mg or 35mg)\nRoutes of Administration: PO\nCommon Trade Names: Enkaid",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Sustained_ventricular_tachycardia": {
          "text": "25mg PO t.i.d\nMay be increased to 35mg PO t.i.d after 3-5 days",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Sustained_ventricular_tachycardia": {
      "text": "25mg PO t.i.d\nMay be increased to 35mg PO t.i.d after 3-5 days",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "Safety and effectiveness in pediatrics not established",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "",
      "subsections": {
        "Pregnancy_Rating": {
          "text": "Category B",
          "tables": []
        },
        "Lactation_risk": {
          "text": "Unknown risk to nursing infants",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed.\nPediatric: N/A",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult: No adjustments needed, but use caution when increasing dosage\nPediatric: N/A",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pregnancy_Rating": {
      "text": "Category B",
      "subsections": {
        "Lactation_risk": {
          "text": "Unknown risk to nursing infants",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed.\nPediatric: N/A",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult: No adjustments needed, but use caution when increasing dosage\nPediatric: N/A",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Lactation_risk": {
      "text": "Unknown risk to nursing infants",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed.\nPediatric: N/A",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult: No adjustments needed, but use caution when increasing dosage\nPediatric: N/A",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Renal_Dosing": {
      "text": "Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed.\nPediatric: N/A",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "Adult: No adjustments needed, but use caution when increasing dosage\nPediatric: N/A",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "Adult: No adjustments needed, but use caution when increasing dosage\nPediatric: N/A",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nPreexisting 2nd or 3rd-degree AV block\nPreexisting right bundle branch block w/ left hemiblock\nPresence of cardiogenic shock",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Provocation or aggravation of ventricular arrhythmias\n2nd or 3rd-degree AV block\nSinus bradycardia",
          "tables": []
        },
        "Common": {
          "text": "Dizziness\nBlurred/abnormal vision\nHeadache",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "Provocation or aggravation of ventricular arrhythmias\n2nd or 3rd-degree AV block\nSinus bradycardia",
      "subsections": {
        "Common": {
          "text": "Dizziness\nBlurred/abnormal vision\nHeadache",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "Dizziness\nBlurred/abnormal vision\nHeadache",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: Genetically determined; 1-2 hours for 90% of patients; 6-11 hours for 10% of patients\n[1]\nMetabolism: Hepatic; Encainide converts to two active metabolites (ODE and MODE)\nExcretion: Urine and feces\nMechanism of action: Blocks sodium channels in purkinje fibers and myocardium; slows conduction, reduces membrane responsiveness, and inhibits automaticity\n[2]",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}